Broad Street Alerts

Small and Mid-Cap Growth Stocks Research and Notifications

JMP Securities Reaffirms “Buy” Rating for Intercept Pharmaceuticals Inc (ICPT)

See Full Report below….

 

About Broad Street Alerts:

 

Big opportunities in Small Cap’s

 

Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our

Members in the last 3 small cap alerts alone!

February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our members gains- 83%

March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.

March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49%

 

for our members.

 

 

 

These are numbers that make traders drool. Any trader in any market would fall all over themselves to

see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and

verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest

of the small-cap newsletters as the best in business. We know with a large following comes a large

responsibility as we have everyone from institutional investors to the beginner following our profiled

securities in our newsletters. This is something we take very seriously always seeking small cap growth

companies that have both near and long-term potential for our members.

 

***Get our small cap profiles, special situation and watch alerts in real time.

We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.

Report:

JMP Securities reissued their buy rating on shares ofIntercept Pharmaceuticals Inc (NASDAQ:ICPT) in a research note issued to investors on Wednesday,Market Beat.com reports. They currently have a $200.00 price target on the biopharmaceutical company’s stock.

Several other analysts have also recently issued reports on the company. Morgan Stanley upgraded Intercept Pharmaceuticals from an underweight rating to an equal weight rating and set a $100.00 target price for the company in a report on Friday, January 29th. Needham & Company LLC reissued a buy rating and issued a $500.00 price objective on shares of Intercept Pharmaceuticals in a report on Wednesday, January 27th. Cowen and Company restated an outperform rating and set a $212.00 price objective on shares of Intercept Pharmaceuticals in a research report on Tuesday, March 8th. Goldman Sachs began coverage on shares of Intercept Pharmaceuticals in a research note on Wednesday, March 30th. They set a neutral rating and a $114.00 target price on the stock. Finally, Barclays decreased their target price on shares of Intercept Pharmaceuticals from $300.00 to $200.00 and set an overweight rating on the stock in a report on Wednesday, February 24th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $253.30.

In other news, insider Lisa Bright sold 241 shares of the stock in a transaction that occurred on Thursday, February 25th. The stock was sold at an average price of $115.22, for a total value of $27,768.02. Following the completion of the sale, the insider now directly owns 19,259 shares of the company’s stock, valued at $2,219,021.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

A number of hedge funds and institutional investors have modified their holdings of the company. CenturyLink Investment Management Co increased its position in shares of Intercept Pharmaceuticals by 94.6% in the fourth quarter. CenturyLink Investment Management Co now owns 2,092 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 1,017 shares during the last quarter. Profund Advisors LLC boosted its stake in shares of Intercept Pharmaceuticals by 0.5% in the fourth quarter. Profund Advisors LLC now owns 12,113 shares of the biopharmaceutical company’s stock worth $1,809,000 after buying an additional 65 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of Intercept Pharmaceuticals by 1.7% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 12,310 shares of the biopharmaceutical company’s stock worth $1,847,000 after buying an additional 200 shares during the last quarter. Bellevue Asset Management AG boosted its stake in shares of Intercept Pharmaceuticals by 55.2% in the fourth quarter. Bellevue Asset Management AG now owns 13,500 shares of the biopharmaceutical company’s stock worth $2,016,000 after buying an additional 4,800 shares during the last quarter. Finally, Polar Capital LLP boosted its stake in shares of Intercept Pharmaceuticals by 3.4% in the fourth quarter. Polar Capital LLP now owns 13,921 shares of the biopharmaceutical company’s stock worth $2,079,000 after buying an additional 462 shares during the last quarter.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 4.914% during mid-day trading on Wednesday, reaching $137.185. The company’s stock had a trading volume of 426,692 shares. Intercept Pharmaceuticals has a one year low of $89.76 and a one year high of $314.88. The company’s market capitalization is $3.34 billion. The stock has a 50-day moving average price of $121.40 and a 200-day moving average price of $147.14.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Tuesday, February 23rd. The biopharmaceutical company reported ($3.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.15) by $0.47. The firm earned $0.45 million during the quarter, compared to analyst estimates of $0.43 million. During the same quarter in the prior year, the company posted ($1.63) EPS. Intercept Pharmaceuticals’s revenue was up .4% on a year-over-year basis. Equities research analysts forecast that Intercept Pharmaceuticals will post ($15.73) EPS for the current year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Company’s product candidate, obeticholic acid (NASDAQ:ICPT), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Source: IRA Market Report

Broad Street Alerts has not been compensated for the mention of _ICPT__ and we do not hold any positions.

Privacy Policy and Disclaimer

Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.
Online Privacy Policy Only
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may reply to this email.
DISCLAIMER
This website/newsletter is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.